Neumocistosis en pacientes venezolanos: diagnóstico y epidemiología (2001-2006)

Panizo, María Mercedes; Reviakina, Vera; Navas, Trina; Casanova, Karina; Sáez, Alejandro; Guevara, Rafael Napoleón; Cáceres, Ana; Vera, Raúl; Sucre, Carlos; Arbona, Esther

doi:10.1016/s1130-1406(08)70054-8

Cited by 12 publications

(12 citation statements)

References 27 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent reports have described an increased rate of PcP in Africa, Asia and South America (Worodria et al , 2003; Aderaye et al , 2007; Le Minor et al , 2008; Panizo et al , 2008; Vray et al , 2008). In this study, we review published studies that have reported the frequency of PcP in developing countries, focusing mainly on more recent data.…”

Section: Introductionmentioning

confidence: 99%

“…Several reports have been published in Venezuela, Brazil and Chile (Panizo et al , 2008; Soeiro et al , 2008). Also, investigations have been conducted in Argentina and Peru (Bava et al , 2002; Eza et al , 2006).…”

Section: Introductionmentioning

confidence: 99%

“…cancer patients) with signs and symptoms of lower respiratory tract infection (Panizo et al , 2008). …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pneumocystis jiroveciipneumonia in developing countries

et al. 2011

View full text Add to dashboard Cite

Pneumocystis pneumonia (PcP) is a serious fungal infection among immunocompromised patients. In developed countries, the epidemiology and clinical spectrum of PcP have been clearly defined and well documented. However, in most developing countries, relatively little is known about the prevalence of pneumocystosis. Several articles covering African, Asian and American countries were reviewed in the present study. PcP was identified as a frequent opportunistic infection in AIDS patients from different geographic regions. A trend to an increasing rate of PcP was apparent in developing countries from 2002 to 2010.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pneumocystis jiroveciipneumonia in developing countries

et al. 2011

View full text Add to dashboard Cite

show abstract

“…[8] Currently, The National Institutes of Health, the Centers for Disease Control and Prevention and the HIV Medicine Association of the Infectious Diseases Society of America guidelines mentions that prophylaxis against PcP may be discontinued safely in HIV-infected individuals when CD4 counts are maintained >200 cells/mm 3 for over 3 months on antiretroviral therapy. [19] Jensen et al . [20] and Masur et al .…”

Section: Discussionmentioning

confidence: 99%

Profile of pneumocystis infection in a tertiary care institute in North India

Kaur

Dewan

2016

Indian J Sex Transm Dis

View full text Add to dashboard Cite

Context:Pneumocystis jirovecii pneumonia (PcP) is still remains a common opportunistic disease in human immunodeficiency virus (HIV) infected individuals. Study on PcP in developing countries are scarce.Aims:To study the occurrence of P. jirovecii infection in clinically suspected individuals in a tertiary care institute.Settings and Design:Retrospective study conducted in a tertiary care hospital.Materials and Methods:Two years data regarding respiratory sample analysis, HIV status, and cluster of differentiation 4 (CD4) cell count of clinically suspected pneumocystis infection patients with known/unknown HIV status were analyzed.Results:Data of 45 eligible patients were analyzed. The majority of the patients were male (between 21 and 50 years of age). Total 26 (57.7%) patients were HIV reactive, of which 14 had CD4 count of <200 cells/mm3. 20 patients (9 HIV reactive and 11 unknown HIV status) were confirmed with pneumocystosis by direct fluorescent antibody (DFA) staining. Four of 14 HIV reactive individuals who had CD4 count of <200 cells/mm3 and 5 of 12 HIV reactive individuals who had CD4 count of >200 cells/mm3 were positive for pneumocystosis.Conclusions:Pneumocystis pneumonia is still prevalent in North India and is mainly affecting patients in economically productive and sexually active age group. To diagnose pneumocystosis, DFA is an easily available method in resource-limited settings. Appreciating the actual HIV or immunodeficiency status and the CD4 profile of an individual with symptoms of pneumocystis infection will help the clinicians in early diagnosis and initiation appropriate therapy in individuals living with the disease.

show abstract

“…Asian countries, such as Thailand, India, and Malaysia, also have high incidences of Pneumocystis infection in the HIV-positive population with diagnosis rates between 12.2–25% (10–12). Developing countries in South America, such as Chile and Venezuela, also report high incidences of Pneumocystis in HIV-positive patients with respiratory symptoms (~37%) (13, 14). More alarming than any individual percentage, the above studies all further the point that Pneumocystis remains a global clinical concern for patients with HIV/AIDS where prophylaxis and/or cART use is limited for a variety of reasons.…”

Section: Epidemiologymentioning

confidence: 99%

Pathological and protective immunity to Pneumocystis infection

Eddens

Kolls

2014

Semin Immunopathol

View full text Add to dashboard Cite

Pneumocystis jirovecii is a common opportunistic infection in the HIV-positive population and is re-emerging as a growing clinical concern in the HIV-negative immunosuppressed population. Newer targeted immunosuppressive therapies and the discovery of rare genetic mutations have furthered our understanding of the immunity required to clear Pneumocystis infection. The immune system can also mount a pathologic response against Pneumocystis following removal of immunosuppression and result in severe damage to the host lung. The current review will examine the most recent epidemiologic studies about the incidence of Pneumocystis in the HIV-positive and HIV-negative populations in the developing and developed world and will detail methods of diagnosis for Pneumocystis pneumonia. Finally, this review aims to summarize the known mediators of immunity to Pneumocystis and detail the pathologic immune response leading to Pneumocystis-related immune reconstitution inflammatory syndrome.

show abstract

Neumocistosis en pacientes venezolanos: diagnóstico y epidemiología (2001-2006)

Cited by 12 publications

References 27 publications

Pneumocystis jiroveciipneumonia in developing countries

Pneumocystis jiroveciipneumonia in developing countries

Profile of pneumocystis infection in a tertiary care institute in North India

Pathological and protective immunity to Pneumocystis infection

Contact Info

Product

Resources

About